Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jan 27

PMID 38279330

Authors

Zena Saleh

Matthew C Moccia

Zachary Ladd

Upasana Joneja

Yahui Li

Francis Spitz

Young Ki Hong

Tao Gao

Affiliations

Soon will be listed here.

Abstract

Pancreatic neuroendocrine tumors (PNETs) are characterized by dysregulated signaling pathways that are crucial for tumor formation and progression. The efficacy of traditional therapies is limited, particularly in the treatment of PNETs at an advanced stage. Epigenetic alterations profoundly impact the activity of signaling pathways in cancer development, offering potential opportunities for drug development. There is currently a lack of extensive research on epigenetic regulation in PNETs. To fill this gap, we first summarize major signaling events that are involved in PNET development. Then, we discuss the epigenetic regulation of these signaling pathways in the context of both PNETs and commonly occurring-and therefore more extensively studied-malignancies. Finally, we will offer a perspective on the future research direction of the PNET epigenome and its potential applications in patient care.

Citing Articles

Evaluation of LRP6, SFRP3, and DVL1 Protein Concentrations in Serum of Patients with Gastroenteropancreatic or Bronchopulmonary Neuroendocrine Tumors.

Duszkiewicz R, Strzelczyk J, Chelmecka E, Strzelczyk J Cancers (Basel). 2025; 17(1.

PMID: 39796676 PMC: 11718808. DOI: 10.3390/cancers17010047.

Pancreatic Neuroendocrine Tumor: The Case Report of a Patient with Germline Mutation and Tumor Analysis Using Single-Cell RNA Sequencing.

Avsievich E, Salimgereeva D, Maluchenko A, Antysheva Z, Voloshin M, Feidorov I J Clin Med. 2025; 13(24.

PMID: 39768544 PMC: 11728285. DOI: 10.3390/jcm13247621.

References

Dyer M, Qadeer Z, Valle-Garcia D, Bernstein E . ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harb Perspect Med. 2017; 7(3). PMC: 5334245. DOI: 10.1101/cshperspect.a026567. View

Luzi E, Marini F, Giusti F, Galli G, Cavalli L, Brandi M . The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit". PLoS One. 2012; 7(6):e39767. PMC: 3384621. DOI: 10.1371/journal.pone.0039767. View

Mohindroo C, McAllister F, De Jesus-Acosta A . Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2022; 36(5):1033-1051. DOI: 10.1016/j.hoc.2022.07.005. View

Cao L, Yang X, Chen Y, Zhang D, Jiang X, Xue P . Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019; 18(1):148. PMC: 6815431. DOI: 10.1186/s12943-019-1075-2. View

Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret J, Souque A . Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology. 2008; 149(6):3137-47. DOI: 10.1210/en.2007-1525. View

Thorns C, Schurmann C, Gebauer N, Wallaschofski H, Kumpers C, Bernard V . Global microRNA profiling of pancreatic neuroendocrine neoplasias. Anticancer Res. 2014; 34(5):2249-54. View

Chakraborty J, Chakraborty S, Chakraborty S, Narayan M . Entanglement of MAPK pathways with gene expression and its omnipresence in the etiology for cancer and neurodegenerative disorders. Biochim Biophys Acta Gene Regul Mech. 2023; 1866(4):194988. DOI: 10.1016/j.bbagrm.2023.194988. View

Kim K, Ryu T, Jung E, Han T, Lee J, Kim S . Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis. Exp Mol Med. 2023; 55(5):952-964. PMC: 10238379. DOI: 10.1038/s12276-023-00987-1. View

Lehman J, Hoeksema M, Staub J, Qian J, Harris B, Callison J . Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer. 2018; 144(5):1104-1114. PMC: 6448409. DOI: 10.1002/ijc.31771. View

10.

Di Domenico A, Pipinikas C, Maire R, Brautigam K, Simillion C, Dettmer M . Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020; 3(1):740. PMC: 7721725. DOI: 10.1038/s42003-020-01479-y. View

11.

Shen X, Wang X, Lu X, Zhao Y, Guan W . Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation. Front Oncol. 2022; 12:967071. PMC: 9554633. DOI: 10.3389/fonc.2022.967071. View

12.

Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J . MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. Sci Rep. 2013; 3:2038. PMC: 3687228. DOI: 10.1038/srep02038. View

13.

Wu T, Zhang X, Huang X, Yang Y, Hua X . Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. J Biol Chem. 2010; 285(24):18291-300. PMC: 2881754. DOI: 10.1074/jbc.M110.106575. View

14.

Kang K, Piao M, Hyun Y, Zhen A, Cho S, Ahn M . Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells. Exp Mol Med. 2019; 51(4):1-14. PMC: 6465248. DOI: 10.1038/s12276-019-0238-y. View

15.

Moschovis D, Vasilaki E, Tzouvala M, Karamanolis G, Katifelis H, Legaki E . Association between genetic polymorphisms in long non-coding RNAs and pancreatic cancer risk. Cancer Biomark. 2018; 24(1):117-123. DOI: 10.3233/CBM-181959. View

16.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

17.

Li Z, Qian J, Li J, Zhu C . Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019; 18(1):435-442. PMC: 6580102. DOI: 10.3892/etm.2019.7629. View

18.

Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P . Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017; 543(7643):65-71. DOI: 10.1038/nature21063. View

19.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

20.

Crabtree J . Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol. 2022; 12:901435. PMC: 9209739. DOI: 10.3389/fonc.2022.901435. View